J&J’s Stelara succeeds in phase 3 ulcerative colitis study
The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary
As per terms of the deal, Boston Pharmaceuticals purchased global rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. The anti-infective drug candidates
In November 2014, Janssen signed an exclusive worldwide collaboration and license agreement with Geron for the development and commercialization of imetelstat in oncology, including hematologic myeloid malignancies. Janssen